Glenmark Pharmaceuticals Inc USA (Glenmark) (BSE: 532296) (NSE: GLENMARK), a research-led, global pharmaceutical company with its head office in India, announced on Friday that it is launching its Ropivacaine Hydrochloride Injection USP, 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) Single-Dose Vials.

The company says that the product is bioequivalent and therapeutically equivalent to the reference listed drug, Naropin2 Injection, 40 mg/20 mL (2 mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL), from Fresenius Kabi USA, LLC NDA - 020533.

Glenmark is to commence distribution of the product in November 2025.

Marc Kikuchi, president & business head, North America, said: "We are pleased to announce the launch of Ropivacaine Hydrochloride Injection USP, 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) Single-Dose Vials. This launch represents another important addition to Glenmark's expanding injectable portfolio and reinforces our dedication to bring quality and affordable alternatives to market for patients in need."